Brazil Resumes Trails for Chinese Vaccines
Brazil Resumes Trails for Chinese Vaccines .Brazil’s National Health Supervision Agency has authorized the resumption of Chinese Kexing COVID-19 vaccine trials in Brazil.
According to previous reports, clinical trials of the vaccine in Brazil were suspended after “serious adverse events occurred.” However, follow-up reports from Brazilian media indicated that the so-called “serious adverse event” was actually a suicide of a vaccine volunteer. The autopsy report showed that the volunteer was 32 years old and the cause of death was suicide.
In a statement issued on the 10th, Kexing Biologics stated that Kexing will continue to communicate with Brazil and expressed “confidence” in the safety of its vaccines. Chinese Foreign Ministry spokesperson Wang Wenbin responded at a press conference on the 10th in response to Brazil’s suspension of the COVID-19 vaccine developed by Beijing Kexing Biological, saying that we have noticed that Beijing Kexing Biological Co., Ltd. has responded to relevant reports. According to the judgment of the Butantan Institute, a partner of Kexing Company in Brazil, the incident has nothing to do with the vaccine, and Kexing Company will continue to maintain communication with Brazil on this.